Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 355-360

  Peng, Qiuping ^a   Zhou, Jinming ^a   Zhou, Qi ^a   Pan, Feng ^a   Zhong, Doping ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Apoptosis; Colorectal neoplasm; Drug resistance; Glycolysis; Hexokinase; RNA interference; Ttiymidylate synthase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; FLUOROURACIL; HEXOKINASE; THYMIDYLATE SYNTHASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; ENZYME ACTIVATION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEXOKINASE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; RNA INTERFERENCE; THYMIDYLATE SYNTHASE; TRANSFECTION;

EID: 67649172726     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in col-orectal cancer-a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 1997; 15: 368-381.
2. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG: Down-regulation of mitochondrial FlFO-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 2005; 65:3162-3170.
3. Warburg O: On the origin of cancer cells. Science 1956: 123: 309-314.
4. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhal-la KN, Keating M J, Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005; 65: 613-621.
5. Pastorino JG, Hoek JB, Shulga N: Activation of glyco-gen synthase kinase 3a disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005; 64:10545-10554.
6. Peng QP, Liang H J, Zhou Q, Zhou JM, Fu XL, Zhong
7. DP: Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition there of. Zhonghua Yi Xue Za Zhi 2007; 87: 1058-1062.
8. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25:4633-4646.
9. Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gate keeper of malignancy when bound to mitochondria. Oncogene 2006; 25:4777-4786.
10. Sui D, Wilson JE: Selective depletion of the Type I, Type II, and Type III isozymes of hexokinase in mammalian cells using small interfering RNAs. Biochem. Biophys. Res. Com-mun. 2004; 319:768-773.
11. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
12. Paul CP, Good PD, Winer I, Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol. 2002; 20:505-508.
13. Grimm SS: Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res. 2004; 64: 85-93.
14. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S: Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007; 26: 7006-7016.
15. Ken G. Energy deregulation licensing tumors to grow. Science 2006 312: 1158-1159.
16. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ: Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 2005; 42: 358-364.
17. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH: Mitochondrial bound type II hexokinase. Biochim. Biophys. Acta. 2002, 1555: 14-20.
18. Robey RB, Hay N: Mitochondrial hexokinases: Guardians of the mitochondria. Cell Cycle 2005; 4: 654-658.
19. Gatenby RA, Gillies RJ: Glycolysis in cancer: A potential target for therapy, Int. J. Biochem. Cell Biol. 2007; 39:1358-1366.
20. Chen Z, Lu WQ, Garcia-Prieto C, Huang P: The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr. 2007; 39: 267-274.
21. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E: Energy metabolism in tumor cells. FEBS. J. 2007: 274 : 1393-1418.
22. Chang JM, Chung JW, Jae HJ, Eh H, Son KR, Lee KC, Park JH: Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model. Acad. Radiol. 2007; 14: 85-92.
23. Dong-Dong L: Small interfering RNA (siRNA) inhibited human liver cancer cell line SMMC7721 proliferation and tumorigenesis. Hepatogastroenterology 2007; 54:1731-1735.
24. Pedersen PL: Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen, J. Bioenerg. Biomembr. 2007; 39: 211-222.
25. Majewski N, Nogueira V, Robey RB, Hay N: Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell Biol. 2004; 24:730-740.
26. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N: Hexokinase mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004; 16:819-830.
27. Rahman L, Voeller D, Rahman M, Lipkowitz S, Alle-gra C, Barrett JC, Kaye FJ, Zajac-Kaye M: Thymidy-late synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell 2004; 5:341-351.